Paper Details
- Home
- Paper Details
Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
Author: AshiharaE, KimuraS, MaekawaT, OhyashikiK, OkabeS, TauchiT
Original Abstract of the Article :
To overcome imatinib resistance, more potent ABL tyrosine kinase inhibitors (TKIs), such as nilotinib and dasatinib have been developed, with demonstrable preclinical activity against most imatinib-resistant BCR-ABL kinase domain mutations, with the exception of T315I. However, imatinib-resistant pa...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1038/onc.2011.3
データ提供:米国国立医学図書館(NLM)
Combating Imatinib Resistance in Chronic Myeloid Leukemia: A Camel's Perspective
Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow. Imatinib, a tyrosine kinase inhibitor, has revolutionized the treatment of CML, but some patients develop resistance to this drug. This study investigated the potential of combining a novel heat shock protein 90 (HSP90) inhibitor, NVP-AUY922, with nilotinib, another tyrosine kinase inhibitor, to overcome imatinib resistance. HSP90 is a protein that helps stabilize and fold other proteins, including BCR-ABL, a protein that plays a key role in CML. By inhibiting HSP90, researchers hope to reduce the levels of BCR-ABL and overcome imatinib resistance.
A Synergistic Approach to Imatinib Resistance
The study found that the combination of AUY922 and nilotinib exhibited a synergistic effect, effectively reducing the outgrowth of resistant cell clones. The combination was more effective than either drug alone in suppressing the growth of CML cells, even those harboring mutations that make them resistant to imatinib. The researchers also observed that the combination prolonged the survival of mice transplanted with CML cells, suggesting its potential for clinical application.
Hope for CML Patients: What This Means for You
This study offers promising new approaches to overcoming imatinib resistance in CML. The combination of AUY922 and nilotinib may provide a valuable treatment option for patients who have developed resistance to imatinib. It's important to note that this study was conducted in preclinical models, and further research is needed to determine its effectiveness in human patients. However, these findings offer hope for individuals battling CML and highlight the importance of ongoing research in developing new and effective cancer treatments.
Dr. Camel's Conclusion
This study underscores the need for innovative strategies in combating cancer. The synergistic effect of combining AUY922 and nilotinib offers a potential solution for overcoming imatinib resistance in CML. Just as a camel can adapt to survive in a harsh desert environment, so too must we adapt our strategies to overcome the challenges posed by cancer. This research provides a glimmer of hope for CML patients and encourages continued efforts to find new and effective treatments for this devastating disease.
Date :
- Date Completed 2011-08-23
- Date Revised 2022-01-14
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.